Premium
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients
Author(s) -
Huang Rui,
Yao Renling,
Wu Weihua,
Wang Jian,
Wu Chao
Publication year - 2019
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15150
Subject(s) - entecavir , medicine , tenofovir , chronic hepatitis , hepatitis b virus , gastroenterology , virology , hepatitis a virus , hepatitis b , virus , lamivudine , oncology , human immunodeficiency virus (hiv)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom